A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

February 1, 2029

Study Completion Date

February 1, 2031

Conditions

LeiomyosarcomaSoft-tissue Sarcomas

Interventions

DRUG

Gemcitabine

Given by IV

DRUG

Nab-Sirolimus

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston